



PRODUCT: **ORGOVYX® (Relugolix)**

COMPANY: Myovant Sciences, Inc.

THERAPEUTIC AREA & INDICATION:
Treatment of advanced prostate cancer

ABOUT THE PRODUCT

At Myovant, we believe men should be empowered with treatment options. ORGOVYX® (relugolix) is the only oral gonadotropin-releasing hormone (GnRH) antagonist approved for the treatment of advanced prostate cancer. As a GnRH antagonist, ORGOVYX blocks the GnRH receptor and reduces production of testosterone, a hormone known to stimulate the growth of prostate cancer. The Phase 3 HERO study demonstrated the efficacy and safety of ORGOVYX, including a 96.7% response rate in testosterone suppression to castrate levels (<50 ng/dL) through 48 weeks. Safety warnings and precautions include QT/QTc interval prolongation, embryo-fetal toxicity, and laboratory testing.